A drug discovery and development company with “first-in-class” drugs for respiratory diseases
Investors
Verona Pharma is listed on the London Stock Exchange under the VRP.L ticker. Read more here about investing in Verona Pharma
Verona Pharma shares
Pipeline
Verona Pharma has a portfolio of new drugs in development for COPD, asthma, cough and anti-inflammatory indications. See our Pipeline
Downloads
Publication in The Lancet Respiratory Medicine
2013 Full Year Results Presentation to Analysts (28 April 2014)
Partners
A key component of Verona Pharma’s business strategy is out-licensing its “first-in-class” drug programmes to suitable development and commercialisation partners. To discuss partnering opportunities, please contact This email address is being protected from spambots. You need JavaScript enabled to view it.
Events and Media
Follow the links below for more information about specific events:
- Dr. Karlsson presents at smi conference in London "COPD: Novel Therapeutics and Management" - 20 and 21 Oct
- Sachs 14th Annual Biotech in Europe Forum for Global Partnering & Investment - 30th Sept to 1st Oct
- Dr. Jan-Anders Karlsson presents "RPL554: a unique respiratory opportunity"
- VIDEO - Verona Pharma CEO speaks about its lead product and business opportunities
- Dr. Jan-Anders Karlsson presents at the Asthma and COPD Conference
- Dr. Jan-Anders Karlsson presents at Therapeutic Area Partnerships
Verona Pharma plc, 3 More London Riverside. London SE1 2RE
Email:
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Tel: +44 (0)203 283 4200
To provide feedback or report problems with the website:
This email address is being protected from spambots. You need JavaScript enabled to view it.